Patients with advanced sarcomas face poor outcomes and have limited treatment options, underscoring the urgent need for innovative therapies. This Phase 1 study evaluated the safety and efficacy ...

Previously, the phase 2 SARC028 trial (NCT02301039) showed that pembrolizumab elicited overall response rates of 23% in patients with metastatic undifferentiated pleomorphic sarcoma and 10% in those ...

There are sensitive preoperative screening tests to detect cervical, endometrial and ovarian occult malignancies but none exists to detect uterine sarcomas. There is almost a complete lack of ...